{"id":16594,"date":"2020-08-07T11:02:45","date_gmt":"2020-08-07T15:02:45","guid":{"rendered":"https:\/\/medicarereport.org\/?p=16594"},"modified":"2020-08-07T11:02:45","modified_gmt":"2020-08-07T15:02:45","slug":"the-fda-accepted-biogens-alzheimers-drug-submission-next-up-a-highly-anticipated-outside-expert-review","status":"publish","type":"post","link":"https:\/\/medicarereport.org\/?p=16594","title":{"rendered":"The FDA accepted Biogen\u2019s Alzheimer\u2019s drug submission. Next up, a highly anticipated outside expert review"},"content":{"rendered":"<p>(By Adam Feuerstein for ST<em>A<\/em>T)<\/p>\n<p>The Food and Drug Administration has agreed to review a marketing application submitted by Biogen for aducanumab, its treatment for Alzheimer\u2019s disease, the company announced Friday.\u00a0 Continue reading article <a href=\"https:\/\/www.statnews.com\/2020\/08\/07\/the-fda-accepted-biogens-alzheimers-drug-submission-next-up-a-highly-anticipated-outside-expert-review\/\">here&#8230;<\/a><\/p>\n<p><a href=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-4372\" src=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png\" alt=\"\" width=\"300\" height=\"32\" srcset=\"https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo-300x32.png 300w, https:\/\/medicarereport.org\/wp-content\/uploads\/2016\/09\/STAT-Logo.png 453w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<pre><strong>Notice:<\/strong> The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link\u2019s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org<\/pre>\n","protected":false},"excerpt":{"rendered":"<p>(By Adam Feuerstein for STAT) The Food and Drug Administration has agreed to review a marketing application submitted by Biogen<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[26,31,15],"tags":[],"class_list":["post-16594","post","type-post","status-publish","format-standard","hentry","category-alzheimersdementia","category-fda","category-part-dprescription-drugs"],"_links":{"self":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/16594","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=16594"}],"version-history":[{"count":1,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/16594\/revisions"}],"predecessor-version":[{"id":16595,"href":"https:\/\/medicarereport.org\/index.php?rest_route=\/wp\/v2\/posts\/16594\/revisions\/16595"}],"wp:attachment":[{"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=16594"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=16594"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicarereport.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=16594"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}